NovoCure Ltd Gross Profit

• NovoCure Ltd showed an increase of +4.4% in Gross Profit from 2024 to 2025.
• This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $23.22 million | Q2 2017: $25.22 million | Q3 2017: $34.96 million | Q4 2017: $38.02 million | Q1 2018: $33.89 million | Q2 2018: $41.68 million | Q3 2018: $45.81 million | Q4 2018: $46.65 million | Q1 2019: $53.50 million | Q2 2019: $65.61 million | Q3 2019: $69.16 million | Q4 2019: $74.45 million | Q1 2020: $77.33 million | Q2 2020: $90.45 million | Q3 2020: $104.27 million | Q4 2020: $115.82 million | Q1 2021: $108.31 million | Q2 2021: $104.92 million | Q3 2021: $103.40 million | Q4 2021: $103.53 million | Q1 2022: $109.82 million | Q2 2022: $112.36 million | Q3 2022: $101.25 million | Q4 2022: $99.54 million | Q1 2023: $92.57 million | Q2 2023: $92.03 million | Q3 2023: $95.23 million | Q1 2024: $104.81 million | Q2 2024: $115.70 million | Q3 2024: $119.72 million | Q1 2025: $116.47 million | Q2 2025: $117.33 million | Q3 2025: $122.48 million.
• Over the full 13 years of available data (2013 to 2025), NovoCure Ltd's Gross Profit has grown by 14,498.7%.
• Historical annual values: Fiscal year 2025: $488.47 million | Fiscal year 2024: $468.04 million | Fiscal year 2023: $381.06 million | Fiscal year 2022: $422.97 million | Fiscal year 2021: $420.15 million | Fiscal year 2020: $387.87 million | Fiscal year 2019: $262.71 million | Fiscal year 2018: $168.02 million | Fiscal year 2017: $121.42 million | Fiscal year 2016: $36.61 million | Fiscal year 2015: $12.48 million | Fiscal year 2014: $5.45 million | Fiscal year 2013: $3.35 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026